Valiant Laboratories Reports Decline in Financial Performance for Q3 2024
Valiant Laboratories, a microcap pharmaceutical company, reported a -23 financial score for the quarter ending September 2024, a decline from the previous quarter. Despite a strong operating cash flow, net sales and profits have decreased, indicating a negative trend. Investors should carefully consider these factors before making any decisions.
Valiant Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.
According to the financial report, Valiant Laboratories has seen a significant decline in its financial performance for the quarter, with a score of -23 compared to -16 in the previous quarter. However, there are some positive aspects to the company's financials.
One of the strengths of Valiant Laboratories is its strong operating cash flow, which has been consistently growing over the past three years. This indicates that the company has been able to generate higher revenues from its business operations.
On the other hand, there are some areas of concern for the company. The net sales for the quarter have fallen by 42.5% compared to the average of the previous four quarters. This indicates a negative trend in sales in the near term. Similarly, the profit before tax and after tax have also seen a significant decline, with a negative trend in the near term.
The company's operating profit margin has also decreased, indicating a decline in efficiency. Additionally, the earnings per share and non-operating income have also shown a negative trend.
Overall, Valiant Laboratories has reported a negative financial performance for the quarter ending September 2024. Investors should carefully consider these factors before making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
